Reach Us +44-1904-929220
Commercialization Of Biomarkers: Diagnostics And Drug Development | 3518

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Commercialization of Biomarkers: Diagnostics and Drug Development

3rd International Conference on Biomarkers & Clinical Research

Michael Sullivan

Keynote: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.008

The commercialization of biomarkers touches on a broad range of scientific areas. In the age of personalized medicine, biomarker analyses are establishing themselves as necessary tools for diagnosis as well as for determining a path for therapy. Screening tests are employed for determining high risk for cancers of the breast, prostate, cervix, and colon. In addition, through companion biomarker analyses, determinations can be made as to the potential effectiveness of treatment (Herceptin, Camptosar, Coumadin). Biomarkers in the contract research organization (CRO) demonstrate how their commercialization is applied to the drug development world. In this realm, biomarker results offer insight into mechanism of action and efficacy, as well as an aid to submission and approval when included in clinical trials. This presentation will touch on concepts of biomarker development for clinical assessment and relay first-hand experience on biomarker analysis for drug development from a CRO perspective.
Michael Sullivan completed his MS degree at the University of Florida. He has worked at Worldwide Clinical Trials- Drug Development Solutions (formerly CEDRA Corporation) for 17 years as a Method Development Scientist, Team Leader, and most recently, Senior Research Fellow. Over the last two years he has focused on the analysis of small molecule biomarkers for CNS studies.
Relevant Topics